Liu, B., Bin, S., Chen, Y., Chen, Z., Wu, X., Zhang, Y., Dong, F., Sun, T., Wu, T., Gan, L., Zong, H., Ouyang, Q. (2025). A new option for post-CDK4/6is resistance era? Multicenter real-world study of anlotinib-based combination therapy in hormone receptor-positive metastatic breast cancer resistant to CDK4/6 inhibitors.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.e13059